The Advanced Clinical Trial Workshop China (ACT China III) was held successfully at Hilton Guangzhou Baiyun, co-organized by CSCO, ASCO Conquer Cancer Foundation and STO from November 22 to 24th in 2013. In the global fight against cancer, the aim of ACT China is to attract and encourage more and more individual researchers and cancer centers engaged in an international level of clinic trials and researches.

ACT China III continued with the high standards in the sessions of discussion and training in academic activities which is co-designed and guided by the well-known experts abroad and CSCO committee members. The participants were the excellent representatives recruited from those who apply online with titles above secondary senior positions and proficiency in English. The invited faculties included Prof. Richard L Schilsky (Former ASCO President), Prof. Martin J. Murphy (Former STO President), Prof. Lillian L. Siu from Princess Margaret Hospital in Canada, Prof. Jack Lee (Expert of Biostatistics in MD Anderson Cancer Center), Dr. Max Ning from FDA, Dr. Francesco Pignatti from EMA, Dr. Chen-Yan Gao from CFDA, Prof. Yi-Long Wu (President of CSCO Executive Committee), Prof. Shu-Kui Qin (Former President of CSCO), Prof. Jin Li (Secretary General of CSCO) and Prof. Shun Lu (Deputy Secretary General of CSCO).

The innovations of ACT China III were three “The First time”, which made it more professional and practical than before as a milestone. It was the first time to accept online application for participation through CSCO website which was fair to provide opportunities to CSCO members. The finally invited list included 37 representatives selected from over 12,000 CSCO members. Meanwhile, it was the first time to have the officers from FDA, CFDA and EMA invited together to introduce their respective regional supervision mechanism on drug clinical trials. It was also the first time to focus on clinical researches of Biomarkers which the courses and topics discussed were set about. It is believed that there will be a great progress and brighter future of the development in the area of Chinese clinical oncology research.